Why does an imported medicine cost more than 200 yuan to 700 thousand?

Recently, a group of children with spinal muscular atrophy have become the focus of media attention. The imported medicine for treating this disease is more than 200 yuan, and it costs 700,000 yuan to get an injection in China. It is said that this imported drug is so expensive because there are fewer children suffering from spinal muscular atrophy, so the drug "has less market demand and high research and development costs, and few pharmaceutical companies pay attention to the research and development of its therapeutic drugs", so it is "expensive".

In recent two years, more and more media have paid attention to the high price of Nocicinasone, a special drug needed to treat these children. According to reports, the price of Noci's needle is 700,000 yuan, and some children need more than one needle a year. There is a case reported by the media, which needs to be injected with Nosina six times a year.

However, there is another reason why the media is so concerned, that is, the price of Nosina Shengna abroad is not high compared with the price of ordinary drugs. For example, this drug costs only 4 1 USD in Australia, equivalent to more than RMB 280, which is "almost free in Japan" ... The price difference between China and foreign countries of a drug is so large that it can't be described as "outrageous".

On August 5, a staff member of the Letters and Calls Office of the National Medical Insurance Bureau said in an interview that the price of Nosina sodium injection is set by the pharmaceutical companies themselves, so the drug prices in different countries are different. "In addition to the raw materials and research and development costs of drugs, pharmaceutical companies will also consider the issue of profit. In addition, the drug is currently monopolized in the domestic market and the price has remained high. "

The staff said that Nocina sodium injection has been included in the medical insurance negotiation agenda since it was listed in China on 20 19, and the country hopes to negotiate with relevant pharmaceutical companies to reduce the drug price to meet the needs of SMA patients. "Since last year, the country has been negotiating with pharmaceutical companies, and the expert group has studied pricing. The specific pricing is not clear. But the inclusion of medical insurance has not been discussed. Because the drug price can't come down, there is always no way to enter the medical insurance catalogue. " The above staff said.

Extended data

This therapeutic drug is also very expensive in developed countries.

It is reported that Nosina sodium injection was developed by Biogen Idec Ltd and was first approved in the United States on February 23, 20 16 16. It is the world's first precise targeted therapy drug for SMA, and then it was approved for the treatment of SMA in the European Union, Brazil, Japan, South Korea, Canada and other countries. From April 28th, 2009 to April 28th, 2065438, Noxii sodium injection was marketed in China, which was used to treat 5qSMA, becoming the first drug to treat SMA in China. Two other drugs for SMA, Risdiplam from Roche and Zolgensma from Novartis, are not listed in China.

The reporter learned that the price of such drugs has been very high, even in the United States, it is a drug that ordinary people can't afford.

From the price point of view, Nosey sodium injection is 1.25 million US dollars (about 870,000 yuan) in the United States. Compared with Noxii sodium injection, which needs repeated injections every year, Zogensma, a subsidiary of Novartis, can complete the treatment at one time, but the price of Zogen SMA is also regarded as "sky-high", reaching as high as 26.5438 million US dollars (about RMB/kloc-0.50 million yuan), and the drug is only listed in the European Union, the United States and Japan.

According to * * * news agency, the price of gene therapy drug "Zolgensma" of sma in Japan is 654.38+67.07 million yen (about RMB1/kloc-0.02 million yuan), which is the most expensive drug in Japan, and the drug target is patients under 2 years old. In May 2020, the Japanese Ministry of Health, Labor and Welfare listed it as the applicable object of public medical insurance.

Shaanxi Legal Network-700,000 yuan for an injection of imported medicine, how cruel.

Upstream news-it's cruel, more than 200 yuan of imported medicine sold for 700 thousand! How to break this game?